GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Umedic Group Bhd (XKLS:0256) » Definitions » ROE %

Umedic Group Bhd (XKLS:0256) ROE % : 10.12% (As of Jan. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Umedic Group Bhd ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Umedic Group Bhd's annualized net income for the quarter that ended in Jan. 2025 was RM7.56 Mil. Umedic Group Bhd's average Total Stockholders Equity over the quarter that ended in Jan. 2025 was RM74.78 Mil. Therefore, Umedic Group Bhd's annualized ROE % for the quarter that ended in Jan. 2025 was 10.12%.

The historical rank and industry rank for Umedic Group Bhd's ROE % or its related term are showing as below:

XKLS:0256' s ROE % Range Over the Past 10 Years
Min: 11.68   Med: 21.89   Max: 45.48
Current: 11.68

During the past 6 years, Umedic Group Bhd's highest ROE % was 45.48%. The lowest was 11.68%. And the median was 21.89%.

XKLS:0256's ROE % is ranked better than
79.9% of 801 companies
in the Medical Devices & Instruments industry
Industry Median: 0.94 vs XKLS:0256: 11.68

Umedic Group Bhd ROE % Historical Data

The historical data trend for Umedic Group Bhd's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Umedic Group Bhd ROE % Chart

Umedic Group Bhd Annual Data
Trend Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
ROE %
Get a 7-Day Free Trial 40.62 45.48 18.78 17.83 13.32

Umedic Group Bhd Quarterly Data
Jul19 Jul20 Jan21 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.00 9.29 17.25 10.12 10.12

Competitive Comparison of Umedic Group Bhd's ROE %

For the Medical Devices subindustry, Umedic Group Bhd's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Umedic Group Bhd's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Umedic Group Bhd's ROE % distribution charts can be found below:

* The bar in red indicates where Umedic Group Bhd's ROE % falls into.



Umedic Group Bhd ROE % Calculation

Umedic Group Bhd's annualized ROE % for the fiscal year that ended in Jul. 2024 is calculated as

ROE %=Net Income (A: Jul. 2024 )/( (Total Stockholders Equity (A: Jul. 2023 )+Total Stockholders Equity (A: Jul. 2024 ))/ count )
=8.991/( (62.994+71.985)/ 2 )
=8.991/67.4895
=13.32 %

Umedic Group Bhd's annualized ROE % for the quarter that ended in Jan. 2025 is calculated as

ROE %=Net Income (Q: Jan. 2025 )/( (Total Stockholders Equity (Q: Oct. 2024 )+Total Stockholders Equity (Q: Jan. 2025 ))/ count )
=7.564/( (73.83+75.721)/ 2 )
=7.564/74.7755
=10.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2025) net income data. ROE % is displayed in the 30-year financial page.


Umedic Group Bhd  (XKLS:0256) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jan. 2025 )
=Net Income/Total Stockholders Equity
=7.564/74.7755
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(7.564 / 46.316)*(46.316 / 86.2445)*(86.2445 / 74.7755)
=Net Margin %*Asset Turnover*Equity Multiplier
=16.33 %*0.537*1.1534
=ROA %*Equity Multiplier
=8.77 %*1.1534
=10.12 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jan. 2025 )
=Net Income/Total Stockholders Equity
=7.564/74.7755
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (7.564 / 9.852) * (9.852 / 9.452) * (9.452 / 46.316) * (46.316 / 86.2445) * (86.2445 / 74.7755)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7678 * 1.0423 * 20.41 % * 0.537 * 1.1534
=10.12 %

Note: The net income data used here is four times the quarterly (Jan. 2025) net income data. The Revenue data used here is four times the quarterly (Jan. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Umedic Group Bhd ROE % Related Terms

Thank you for viewing the detailed overview of Umedic Group Bhd's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Umedic Group Bhd Business Description

Traded in Other Exchanges
N/A
Address
PMT 790, Jalan Cassia Selatan 5/2, Taman Perindustrian Batu Kawan, Pulau Pinang, Bandar Cassia, PNG, MYS, 14110
Umedic Group Bhd is principally involved in the marketing and distribution of various branded medical devices and consumables as well as the provision of after-sales service for all products. The company is also involved in developing, manufacturing, and marketing of medical consumables. It has two reportable segments: marketing and distribution, which includes marketing and distribution of medical devices and the provision of after-sales service; the manufacturing segment includes developing, manufacturing, and marketing of medical devices. The company generates the majority of its revenue from the marketing and distribution segment. The company has customers in Asia Pacific, Americas, Europe, Middle East, Africa, and Oceania geographically.

Umedic Group Bhd Headlines

No Headlines